Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said on Tuesday.
Source link
Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay
You May Also Like
More From Author
Economists Wake Up to West’s Trade and Technology Dependence on China
